Log in to your Inderes Free account to see all free content on this page.
Medivir
2.89
SEK
+0.35 %
MVIR
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 following
www.medivir.com/investors
Medivir is a pharmaceutical company. The company develops drugs and treatments with a focus on cancers and other serious diseases. The company invests in indication areas where available treatment methods are limited or completely lacking research. Collaborations with other partners are part of the business model, and drug development, as well as commercialization, are conducted either in-house or in partnership with other pharmaceutical companies. The head office is located in Huddinge.
Revenue
7.6M
EBIT %
-1,202.63 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
MVIR
Daily low / high price
2.7 / 2.89
SEK
Market cap
331.25M SEK
Turnover
319.81K SEK
Volume
114K
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Linc AB | 11.2 % | 11.4 % |
Nordea Funds AB | 8.7 % | 8.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
MEDIVIR AB – INTERIM REPORT JANUARY – SEPTEMBER 2024
BioStock: Medivir signs new clinical trial collaboration with Eisai
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio